Macular Degeneration (cont.)
Andrew A. Dahl, MD, FACS
Andrew A. Dahl, MD, is a board-certified ophthalmologist. Dr. Dahl's educational background includes a BA with Honors and Distinction from Wesleyan University, Middletown, CT, and an MD from Cornell University, where he was selected for Alpha Omega Alpha, the national medical honor society. He had an internal medical internship at the New York Hospital/Cornell Medical Center.
William C. Shiel Jr., MD, FACP, FACR
Dr. Shiel received a Bachelor of Science degree with honors from the University of Notre Dame. There he was involved in research in radiation biology and received the Huisking Scholarship. After graduating from St. Louis University School of Medicine, he completed his Internal Medicine residency and Rheumatology fellowship at the University of California, Irvine. He is board-certified in Internal Medicine and Rheumatology.
In this Article
- Macular degeneration facts
- What is macular degeneration?
- What is the retina?
- What is the macula?
- What is age-related macular degeneration (AMD)?
- What is wet age-related macular degeneration?
- What are retinal drusen?
- What is dry age-related macular degeneration?
- What causes macular degeneration?
- What are risk factors for age-related macular degeneration?
- What are macular degeneration symptoms?
- What are signs of macular degeneration?
- What type of specialist treats macular degeneration?
- What tests do health care professionals use to diagnose macular degeneration?
- What is the treatment for wet macular degeneration?
- What is the treatment for dry macular degeneration?
- What are complications of macular degeneration?
- What is the prognosis for macular degeneration?
- Is it possible to prevent macular degeneration?
- What research is being done on macular degeneration?
- Find a local Eye Doctor in your town
What is the treatment for wet macular degeneration?
Wet AMD can be treated with laser surgery, photodynamic therapy, and injections into the eye. None of these treatments is a permanent cure for wet AMD. The disease and loss of vision may progress despite treatment.
Laser surgery in the form of photocoagulation is used to destroy the fragile, leaky blood vessels. A high energy beam of light is aimed directly onto the new blood vessels to eradicate them, preventing further loss of vision. However, laser treatment may also destroy some surrounding healthy tissue and some vision. Because of this, only eyes with new vessels away from the exact center of the vision can be treated. This represents only a small proportion of patients with AMD. Laser surgery is only effective in halting or slowing visual loss if the leaky blood vessels have developed away from the fovea, the central part of the macula. Even in treated cases, the risk of new blood vessels recurring after treatment is significant and further or other treatment may be necessary.
Photodynamic therapy uses a drug called verteporfin (Visudyne) that is being injected into a vein of the arm. A light of a specific wavelength is then directed into the eye to activate the drug adhering to the blood vessels in the eye. The activated drug destroys the new blood vessels and leads to a slower rate of vision decline. Photodynamic therapy may slow the rate of vision loss. It does not stop vision loss or restore vision in eyes already damaged by advanced AMD. Treatment results often are temporary. Retreatment may be necessary.
Within the last 11 years, injections into the eye with drugs specifically developed to stop the growth of new blood vessels have revolutionized the treatment of wet macular degeneration and have become the mainstay of treatment of wet macular degeneration. We have learned that a specific chemical called vascular endothelial growth factor (VEGF) is necessary for the new blood vessels to grow under the retina. Drugs that counter VEGF (anti-VEGF pharmacotherapy) can be injected into the eye to arrest development of new blood vessels and sometimes cause them to regress. These drugs include Eylea (aflibercept) and Lucentis (ranibizumab), both approved by the FDA for this indication, and Avastin (bevacizumab), which is unapproved by the FDA for injection into the eye and requires compounding by a specialized pharmacy. These drugs include Eylea and Lucentis, both approved by the FDA for this indication, and Avastin, which is unapproved by the FDA for injection into the eye and requires compounding by a specialized pharmacy. Some physicians preferentially use Avastin because of its much lower cost. These drugs are injected into the vitreous of the eye in the ophthalmologist's office and may need to be given as frequently as monthly. Careful observation of the eye on a monthly basis to determine the drug effect is necessary in the case of Lucentis and every other month in the case of Eylea. With this treatment, visual loss can often be halted or slowed and some patients will even experience some improvement of vision. Newer drugs currently under review may need to be given less frequently. Photodynamic therapy and laser ablation have been largely, if not completely, abandoned in favor of VEGF inhibitors. New and more effective anti-VEGF medicines, including drugs that counter platelet derived growth factors and angiopoietins are currently in clinical trials and approaching the market. If diagnosed and treated early, the patient's chances of a better outcome are improved.
In patients with far advanced macular degeneration on both eyes, surgery to implant a telescopic lens in one eye is an option. The telescope implant, which surgically replaces the eye's natural lens, magnifies images while reducing the field of vision (peripheral vision). The telescopic lens implant may improve both distance and close-up central vision.
Get breaking medical news.